Sagimet Biosciences Announces Phase 3 Trial Success

Sagimet Biosciences, Inc. Class A ( (SGMT) ) has provided an announcement.

On June 4, 2025, Sagimet Biosciences announced that its license partner, Ascletis Bioscience Co. Ltd., successfully met all primary and secondary endpoints in a Phase 3 clinical trial for denifanstat, a treatment for moderate to severe acne vulgaris in China. This achievement underscores the potential of FASN inhibitors as a novel therapeutic approach for acne, a condition affecting millions globally. Additionally, Sagimet has initiated a Phase 1 clinical trial in the U.S. for another FASN inhibitor, TVB-3567, aimed at treating acne, highlighting the company’s strategic expansion in the dermatological space.

The most recent analyst rating on (SGMT) stock is a Buy with a $15.00 price target. To see the full list of analyst forecasts on Sagimet Biosciences, Inc. Class A stock, see the SGMT Stock Forecast page.

Spark’s Take on SGMT Stock

According to Spark, TipRanks’ AI Analyst, SGMT is a Neutral.

Sagimet Biosciences’ overall score reflects substantial financial difficulties marked by persistent losses and reliance on external funding. While technical indicators show short-term bullish momentum, the lack of profitability and negative equity pose significant long-term risks. Valuation metrics further highlight the challenges in viewing this stock as an attractive investment.

To see Spark’s full report on SGMT stock, click here.

More about Sagimet Biosciences, Inc. Class A

Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company focused on developing novel therapeutics targeting dysfunctional metabolic and fibrotic pathways. The company is particularly known for its development of fatty acid synthase (FASN) inhibitors, with its lead drug candidate, denifanstat, being developed for the treatment of metabolic dysfunction associated steatohepatitis (MASH).

Average Trading Volume: 506,507

Technical Sentiment Signal: Sell

Current Market Cap: $107.1M

Learn more about SGMT stock on TipRanks’ Stock Analysis page.